Tirzepatide Medical Weight Loss in Newport Beach
GLP-1 medication has changed what is possible for weight loss. Tirzepatide produces results that diet and exercise alone rarely achieve — not because it replaces effort, but because it addresses the metabolic and hormonal drivers of weight gain that effort alone cannot override.
Tirzepatide (commercially available as Mounjaro and Zepbound) is a dual GIP and GLP-1 receptor agonist — the first of its class. By acting on two incretin hormone pathways simultaneously, it produces more significant weight loss, better metabolic improvement, and stronger appetite regulation than single-agonist GLP-1 medications like semaglutide. Clinical trials have shown average weight loss of 20 to 22% of body weight over 72 weeks — results that were previously achievable only through bariatric surgery.
At Plump Medical Spa in Newport Beach, Dr. Amir Mortazavi, MD prescribes and manages Tirzepatide as part of a comprehensive metabolic program — addressing weight loss, body composition, metabolic health, and the aesthetic changes that accompany significant weight loss. The medication is one component of a physician-supervised approach, not a standalone prescription.
Tirzepatide is a physician-prescribed medication requiring medical oversight. At Plump, Dr. Mortazavi conducts a full medical evaluation before prescribing — reviewing health history, contraindications, and metabolic goals. This is not a telehealth prescription service. It is a supervised medical program with ongoing monitoring and dose optimization.
Why Tirzepatide over other GLP-1 medications
GIP + GLP-1 — two pathways, better results
Semaglutide (Ozempic/Wegovy) acts on GLP-1 receptors only. Tirzepatide acts on both GIP and GLP-1 receptors simultaneously. This dual mechanism produces greater appetite suppression, superior metabolic improvements, and more significant weight loss than single-agonist medications in head-to-head comparisons.
Up to 22% body weight loss
The SURMOUNT clinical trial program demonstrated average weight loss of 20 to 22% of body weight over 72 weeks at the highest doses — comparable to outcomes previously seen only with bariatric surgery. For most patients, this represents a meaningfully different category of result than prior weight loss medications.
The comprehensive approach at Plump
Tirzepatide is a powerful tool. How it is used determines how well it works and whether results are maintained. Dr. Mortazavi approaches medical weight loss as a physician — not a prescription service — integrating the medication with metabolic assessment, dose optimization, and attention to the body composition and aesthetic changes that accompany significant weight loss.
Full medical evaluation
Health history, contraindications, current medications, and metabolic goals are reviewed before prescribing. Tirzepatide has specific contraindications including personal or family history of medullary thyroid carcinoma and MEN2. These are identified and discussed at consultation.
Baseline metabolic assessment
Starting weight, body composition, blood glucose, HbA1c, lipid panel, and other relevant metabolic markers are established before treatment begins. This creates a baseline against which improvement is measured and provides clinical context for dose decisions.
Dose titration and optimization
Tirzepatide is started at a low dose and titrated upward based on the patient’s tolerance and response. The goal is the lowest effective dose that produces meaningful weight loss with manageable side effects — not maximum dose for maximum speed. Dr. Mortazavi manages this titration personally throughout the program.
Aesthetic integration
Significant weight loss changes the face and body in ways that benefit from aesthetic attention — facial volume loss from rapid weight reduction, skin laxity in the body, and changes in facial proportion that affect how patients look at their new weight. Dr. Mortazavi considers the full picture and coordinates aesthetic treatments where appropriate as weight loss progresses.
Pricing
Tirzepatide at Plump is priced by dose tier. The appropriate starting dose and progression are determined at consultation based on the patient’s medical history, weight loss goals, and metabolic profile.
What to expect
Starting treatment
Most patients begin at 2.5 mg weekly for the first 4 weeks before titrating upward. This slow start significantly reduces the nausea and GI side effects that are the most common reason patients discontinue GLP-1 medications. The titration schedule is managed by Dr. Mortazavi based on each patient’s tolerance and response.
Side effects
The most common side effects of Tirzepatide are nausea, reduced appetite, and mild GI discomfort — particularly during dose increases. These are typically mild to moderate and improve over 2 to 4 weeks at each new dose. Severe or persistent side effects are discussed with Dr. Mortazavi directly, who adjusts the titration schedule accordingly. Starting low and going slow is the most effective way to minimize side effects.
Timeline
Most patients notice appetite reduction and early weight loss within the first 2 to 4 weeks. Significant weight loss is typically apparent by 3 months and continues progressively through the first year. The full benefit of the highest doses is typically realized at 9 to 12 months of treatment.
Maintenance and discontinuation
Weight regain after discontinuing GLP-1 medication is well-documented — the medication addresses the biological drivers of appetite and metabolism, and these return when it is stopped. Dr. Mortazavi discusses long-term strategy at consultation, including the role of Tirzepatide as an ongoing maintenance tool versus a time-limited intervention, and what realistic expectations for weight maintenance look like.
Dr. Mortazavi’s background in internal medicine gives him a clinical perspective on metabolic weight management that goes beyond simply prescribing a medication. He approaches Tirzepatide as one component of a broader metabolic and aesthetic program — monitoring health markers, managing dose titration, and coordinating the aesthetic treatments that address how the body and face change with significant weight loss. All consultations and prescriptions are personally managed.
Frequently asked questions
What is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist — a weekly injectable medication that reduces appetite, slows gastric emptying, and improves insulin sensitivity. It is commercially available as Mounjaro (approved for type 2 diabetes) and Zepbound (approved for weight loss). Clinical trials have demonstrated average weight loss of 20 to 22% of body weight over 72 weeks at the highest doses, making it the most effective weight loss medication currently available.
How is Tirzepatide different from Ozempic or semaglutide?
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist only. Tirzepatide acts on both GIP and GLP-1 receptors simultaneously — this dual mechanism produces greater appetite suppression, superior metabolic improvements, and more significant weight loss than semaglutide in clinical comparisons. Head-to-head trials have shown Tirzepatide produces approximately 5 to 8% more total body weight loss than semaglutide at comparable doses.
Will I regain weight when I stop Tirzepatide?
For most patients, yes — at least partially. Tirzepatide addresses the biological drivers of appetite and metabolic rate that make weight maintenance difficult. When the medication is stopped, these factors return. Clinical data shows that patients regain an average of two-thirds of their lost weight within a year of discontinuation without ongoing intervention. Dr. Mortazavi discusses long-term strategy at consultation so patients understand this before starting.
What are the most common side effects?
Nausea, reduced appetite, and mild GI discomfort are the most common, particularly during dose increases. These typically improve over 2 to 4 weeks at each new dose level. Starting at a low dose and titrating slowly — which is Dr. Mortazavi’s standard approach — significantly reduces side effect severity. Most patients find side effects very manageable after the initial titration period.
Who is not a candidate for Tirzepatide?
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). It is also not appropriate for patients with a history of pancreatitis, certain GI conditions, or who are pregnant or planning pregnancy. Dr. Mortazavi reviews all contraindications thoroughly at the medical evaluation before prescribing.
How much does Tirzepatide cost at Plump?
Tirzepatide at Plump Medical Spa in Newport Beach is $600 per month for low dose (up to 5 mg weekly) and $800 per month for medium dose (up to 10 mg weekly) on a monthly subscription. Higher doses of 12.5 mg and 15 mg are $450 per injection. The appropriate dose and progression are determined at consultation based on your medical history and weight loss goals.
Related treatments
Weight loss often benefits from coordinated aesthetic treatments as body composition changes.
Schedule a consultation
Tirzepatide medical weight loss is available at Plump Medical Spa in Newport Beach, serving patients throughout Orange County and Southern California.
4667 MacArthur Blvd, Suite 310 — Newport Beach, CA 92660
(949) 568-7544 — info@plumpmedicalspa.com
Tuesday – Saturday, 10am – 6pm — By Appointment Only